RxDoctor Payments Data

Frank Ruda, MD

Ophthalmology · The Woodlands, TXNPI 1952561870

Payments from drug & device makers

$23,486in general payments, 2019–2025

Across 144 payments — averaging $163.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Regeneron Healthcare Solutions, Inc.$10K
  • Regeneron$10K
  • AbbVie$795
  • Alcon$542
  • Genentech USA, Inc.$486
  • Astellas Pharma US Inc$363
  • plus $1K from 16 others

What the payments were for

  • Consulting fees$8,68837%
  • Speaking & faculty fees$8,40336%
  • Travel & lodging$6703%
  • Food & beverage$5,70524%
  • Gifts$190%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$23,486 in reported general payments places this provider in the 85th percentile of 1,355 ophthalmology providers in Texas.

See all ophthalmology providers in Texas

Medicare billing

Part B allowed, 2024
$1,998,086
Medicare patients
627
Services billed
9,930

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LumiganBimatoprost12$7,588
Prednisolone Acetate181$5,425
CombiganBrimonidine Tartrate/Timolol12$4,630
Bromfenac Sodium16$2,416
MoxifloxacinMoxifloxacin Hcl88$2,160
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol19$1,766
Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha95$1,006
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat65$955
Latanoprost93$695
Atropine Sulfate18$569
Ketorolac Tromethamine17$446
Brimonidine Tartrate39$435
Cyclopentolate Hcl34$397
Timolol Maleate29$200
Dorzolamide Hcl11$199

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan, Combigan$795$12,21824 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,355 ophthalmology providers in Texas.

Other ophthalmology in The Woodlands

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →